Obexelimab
As of the edition of 20 October 2026, Obexelimab is an antibody: in active development; acts on CD19 and FCGR2B.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2023
- Kind
- Antibody
- Registered trials
- 7, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 2 | 2 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Xencor | Lead sponsor of trials | 2016 to now |
| Zenas BioPharma | Lead sponsor of trials | 2023 to now |